BioSmart Co.Ltd (038460) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BioSmart Co.Ltd stock KRW 6,675, price KRW 2,225, upside +200.0%, quality 42 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,225 KRW – 9,290 KRW · fair‑value band 4,830 KRW – 7,984 KRW · the 2,225 KRW price screens below the 6,675 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow BioSmart Co.Ltd in your weekly email
Every Wednesday you see whether BioSmart Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioSmart Co.,Ltd. manufactures and sells magnetic stripe (MS) cards in South Korea. The company's magnetic stripe cards include credit cards, smart cards, traffic cards, securities cards, etc.
Show moreShow less
It also sells card equipment, such as traffic card issuing machinery, smart card issuing machinery, credit card issuing machinery, etc.; provides card issuing services comprising MS card and IC chip personalization, and photo-transferring; and develops software programs related to credit card issuing.
The company was formerly known as KBC Corporation and changed its name to BioSmart Co.,Ltd. in March 2007. BioSmart Co.,Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.
Stock analysis
BioSmart Co.Ltd (038460) currently trades at 2,225 KRW, while our model-based Fair Value estimate is 6,675 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 11,461 KRW per share, and 14 of the 14 models we run sit above the 2,225 KRW price.
Bear case: the Asset-Based group reads lowest at 3,579 KRW, and 0 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: 4,830 KRW (bear) to 7,984 KRW (bull), the price of 2,225 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BioSmart Co.Ltd reported revenue of 483B KRW in FY2025 versus 189B KRW in FY2021, a compound +26.4%/yr. Reported net income was 9.0B KRW in FY2025, compounding +59.5%/yr from FY2021.
Key figures
Market cap 62.7B KRW (≈ $46.3M) Micro · P/S ratio 0.19 · Net margin 0.7% · Return on equity −178% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 2.7% · Revenue (TTM) 333B KRW · Revenue growth (YoY) +94.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at 22% fair-value upside, at 200%, 038460 screens cheaper than that median.
Fair Value models
Bear4,830 KRWFair Value 6,675 KRWBull7,984 KRW
Price 2,225 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
Start year 2020 (pandemic). Over 10 years: +24.4% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.6% vs 25.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 5%
2025 sits 849% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Equipment & Parts · 17 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets2.9% · Above median
Net margin (12 months)0.7% · Bottom 25%
Operating margin (12 months)2.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)94.2% · Top 25%
Balance sheet
Debt / equity0.19× · Highest 25%
Valuation Multiplesvs Electronic Equipment & Parts median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BioSmart Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/038460
Frequently asked questions
Is BioSmart Co.Ltd (038460) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 6,675 KRW versus a price of 2,225 KRW, about +200% upside (undervalued).
What is the fair value of 038460?
Our model-based fair value for BioSmart Co.Ltd is 6,675 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 2,225 KRW.
What is the quality score of 038460?
BioSmart Co.Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioSmart Co.Ltd (038460)?
Our model-based price target is the fair value of 6,675 KRW (as of Nov 9, 2026) from 14 valuation models. Cautious scenario 4,830 KRW, optimistic scenario 7,984 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BioSmart Co.Ltd stock forecast for 2026?
Our models put fair value at 6,675 KRW, about +200% upside versus a price of 2,225 KRW (undervalued). Cautious scenario 4,830 KRW, optimistic scenario 7,984 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BioSmart Co.Ltd (038460)?
BioSmart Co.Ltd reported trailing-twelve-month revenue of about 333B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of BioSmart Co.Ltd (038460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioSmart Co.Ltd it is 6,675 KRW per share (as of Nov 9, 2026), against a price of 2,225 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is BioSmart Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 038460 trades below its calculated fair value: price 2,225 KRW, fair value 6,675 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 038460?
No. The price is what the market pays today (2,225 KRW); the fair value is what the company's own numbers justify (6,675 KRW). For BioSmart Co.Ltd the two are 4,450 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BioSmart Co.Ltd worth?
The market values BioSmart Co.Ltd at about 62.7B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 2,225 KRW; our models calculate a fair value of 6,675 KRW per share.
What do the bullish and bearish scenarios say about 038460?
Our models span a range for BioSmart Co.Ltd: cautious scenario 4,830 KRW, base 6,675 KRW, optimistic 7,984 KRW per share (as of Nov 9, 2026, price 2,225 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioSmart Co.Ltd (038460)?
Balance-sheet figures for BioSmart Co.Ltd (as of Nov 9, 2026): return on equity −178.1%, debt of 0.19 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 038460 from its 52-week high?
BioSmart Co.Ltd trades at 2,225 KRW, about 64% below its 52-week high of 6,250 KRW and at the low of 2,225 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 6,675 KRW is for.
Which stocks are comparable to BioSmart Co.Ltd?
From the same area (Technology) we also value VINATech Co, Amotech Co, KHVATEC Co, Namuga Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioSmart Co.Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 2,225 KRW, calculated fair value 6,675 KRW (+200%), Quality Score 42/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 038460 calculated?
We run BioSmart Co.Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6,675 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioSmart Co.Ltd currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioSmart Co.Ltd (038460)?
The closing price on Nov 6, 2026 was 2,225 KRW. Our model-based fair value is 6,675 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioSmart Co.Ltd right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (4,830 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of BioSmart Co.Ltd
How large is the market capitalisation of BioSmart Co.Ltd (038460)?
The market capitalisation of BioSmart Co.Ltd is 62.7B KRW (≈ $46.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioSmart Co.Ltd (038460)?
The price-to-sales ratio of BioSmart Co.Ltd is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of BioSmart Co.Ltd (038460)?
The net margin of BioSmart Co.Ltd is 0.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioSmart Co.Ltd (038460)?
The return on equity (ROE) of BioSmart Co.Ltd is −178% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioSmart Co.Ltd (038460)?
On an EBIT basis the return on assets of BioSmart Co.Ltd is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioSmart Co.Ltd (038460)?
The operating margin of BioSmart Co.Ltd is 2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioSmart Co.Ltd (038460)?
Revenue at BioSmart Co.Ltd is growing +94.2% versus a year earlier (3y avg +7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioSmart Co.Ltd (038460)?
Earnings per share at BioSmart Co.Ltd are growing +171% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BioSmart Co.Ltd (038460) generate?
The free cash flow of BioSmart Co.Ltd is −9.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BioSmart Co.Ltd (038460) carry?
The net debt of BioSmart Co.Ltd is 41.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioSmart Co.Ltd in the live analysis
One click puts BioSmart Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026